NDAORALSYRUP
Approved
Mar 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KENACORT (triamcinolone diacetate) is an oral corticosteroid syrup approved in 1961 for inflammatory and allergic conditions. It is a small-molecule glucocorticoid that suppresses immune and inflammatory responses across multiple indications. The drug is administered orally, making it accessible for pediatric and adult populations who cannot tolerate injections.
LOE Approaching
As LOE approaches, the brand team is likely contracting, with roles shifting from growth to maintenance and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KENACORT offers limited career growth opportunities given the LOE-approaching lifecycle stage and zero linked job openings. Roles are typically defensive, focused on managing generic competition and transitioning from brand to generic support rather than driving innovation or market expansion.
Brand ManagerField Sales Representative
Worked on KENACORT at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.